An FDA advisory committee is meeting on Thursday to discuss whether flibanserin — a drug sometimes nicknamed ‘women’s viagra’ — should be approved to treat low libido in women.
If approved, the drug would be marketed as treatment for hypoactive sexual desire disorder, which is said to cause a low sex drive in women. Some supporters argue the drug has a role in gender equality and that women do not have the same resources as men to deal with various degrees of sexual dysfunction.
The drug, owned by Sprout Pharmaceuticals, has been rejected by the agency two times already. The argument being that its benefit is not notable enough to outweigh its side effects which can include dizziness and nausea.
Other pharmaceutical companies including Pfizer and Procter & Gamble have made attempts at drugs to treat lack of libido among women. So far they have not been successful.
The FDA’s Thursday meeting on flibanserin is open to the public.
Get our Health Newsletter. Sign up to receive the latest health and science news, plus answers to wellness questions and expert tips.
